TNFSF15 and autoimmune disease: Deficiency in DR3, TL1A, or treatment with TL1A blocking antibodies ameliorates a broad array of autoimmune disease models, including experimental allergic encephalomyelitis, allergic lung hypersensitivity, experimental arthritis, and inflammatory bowel disease [4, 7–12].